logo-loader
viewCello Health PLC

Cello Health grows interim profits and eyes further acquisitions

Chief executive Mark Scott said strong growth was notable in the US market and that Health Communications and Health Consulting “made particularly pleasing progress”

Cello Health PLC technology and expertise
Cello provides expertise spanning the pharmaceutical, biotechnology, diagnostics, equipment and consumer sectors

Cello Health PLC (LON:CLL) reported good growth in profits and strong cash flow for the first half of the year said it was confident about the rest of the year too.

The healthcare-focused advisory group delivered net revenue of £54.5mln for the first six months of the year, which was up 6.8% on a year ago, with like-for-like constant currency net revenue up 4.5%.

WATCH: Cello Health reports good growth in profits and strong cash flow

Of the group’s two divisions, Health provided the bulk of growth, with revenue up 11.6% and like-for-likes of 8.2%, while Signal, which is historically second-half-weighted, was pretty much flat on a net revenue basis, with like-for-likes down 1%.

Chief executive Mark Scott said strong growth was notable in the US market and that Cello Health Communications and Cello Health Consulting “made particularly pleasing progress”.

The August acquisition of Innovative Science Solutions, a US-based scientific consulting firm specialising in strategic counsel and regulatory support, will help contribute to this momentum, Scott added, highlighting the critical regulatory expertise ISS has added.

Underlying profit before tax and earnings per share for the first half were both up 12.7% to £5.7mln and 4.08p respectively, with PBT and EPS rising 40% on a statutory basis.

Keeping up its unbroken 13-year progressive dividend history, the interim payout was lifted 4.5% to 1.15p per share.

On the outlook, the company said trading had continued to be good over the summer, further acquisitions being appraised and good revenue visibility "gives us confidence for a strong full year outcome”.

Cello shares were up 1.6% to 125p on Wednesday morning.

Quick facts: Cello Health PLC

Price: 126.25 GBX

AIM:CLL
Market: AIM
Market Cap: £134.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cello Health PLC named herein, including the promotion by the Company of Cello Health PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Cello Health reports good growth in profits and strong cash flow

Cello Health PLC's (LON:CLL) Mark Scott tells Proactive London they've seen good growth in profits and strong cash flow for the first half of the year said that he's confident about the rest of the year too. The group delivered net revenue of £54.5mln for the first six months of the year,...

on 18/9/19

RNS

Total Voting Rights

1 week, 2 days ago

Holding(s) in Company

2 weeks, 6 days ago

Holding(s) in Company

4 weeks ago

Total Voting Rights

4 weeks, 1 day ago

Total Voting Rights

on 7/10/19

Disposal

on 2/10/19

Interim Results

on 18/9/19

2 min read